Carbon ion therapy has demonstrated unique advantages and reliable efficacy for tracheal tumors—whether primary squamous cell carcinoma or adenoid cystic carcinoma of the trachea, or secondary tracheal invasion from other malignancies. The following summarizes our center's recent treatment experiences and data for reference by colleagues and patients alike.

Hold hands with Dongli to enjoy a quantum health lifestyle. The 3A-level ecological garden-style Dongli Hotel has officially opened in the Kangyang (Wellness) Town of Wuwei Tumor Hospital, integrating cultural experiences, quantum healing, and traditional Chinese medicine therapy. It offers diverse accommodation options and professional care services, setting a new benchmark for "culture + wellness + tourism."

The Lanzhou Heavy Ion Center has completed a clinical analysis of 61 rectal cancer patients treated with heavy (carbon) ion therapy, achieving a median survival time of 54 months. For patients with stage III/IV or recurrent/refractory disease, this technology offers significantly extended survival due to its high precision, low side effects, and sphincter-sparing advantages, providing a new treatment option for those ineligible for surgery or resistant to radiotherapy and chemotherapy.

Introduction to the definition of superficial refractory tumors and the three core advantages of heavy (carbon) ion therapy: precise targeting via the Bragg peak, ultra-high biological effectiveness, and flexible dose modulation. The Gansu Wuwei Heavy Ion Center, utilizing domestically produced equipment, has successfully treated over 2,800 difficult cases—including sarcomas and recurrent breast cancer on the chest wall—that had failed conventional therapies, offering new hope to patients who had lost all hope.

The Wuyi Heavy Ion Center's HFOV technology achieves respiratory motion control within 1mm, enhancing the accuracy of heavy ion radiotherapy. By using high-frequency oscillatory ventilation, it ensures the stability of the tumor target area, improving treatment safety and efficacy.

A summary analysis of 77 cases of chordoma treated with heavy ion (carbon ion) therapy at the Wuwei Heavy Ion Medical Center, demonstrating its high efficacy and low toxicity, suitable for patients with complex and large chordomas, especially those who are difficult to resect surgically or have recurrent after surgery.

Since the first heavy ion device in China was established in Wuwei, Gansu in 2012, we have developed an inseparable connection with particle therapy for cancer. From that time on, we embarked on the journey of constructing China's first heavy ion device.

A real-world data study of 170 cases of liver cancer treated with heavy ion therapy in Wuwei reveals survival breakthroughs, with a median survival period of 37 months and a 5-year survival rate of 41.01%, demonstrating the outstanding value of China's advanced technology in the treatment of liver cancer.

Brain tumors are the focus and difficulty in the field of radiation therapy, mainly including two types: primary brain gliomas and secondary brain metastases. The Wuwei Heavy Ion Center, relying on China's first heavy (carbon) ion therapy system, has accumulated rich clinical experience in the treatment of brain tumors. Since the first patient received heavy (carbon) ion therapy in November 2018, as of March 2026, the center has treated a total of 198 patients with brain tumors, including 76 patients with brain gliomas and 122 patients with brain metastases, totaling 198 cases of brain tumors.

Analysis of the therapeutic effect of (carbon) ion therapy for 164 sarcoma patients at the Wuwei Ion Medical Center, with a local control rate approaching 100% and significant survival rates, suitable for complex locations and refractory sarcomas, demonstrating high safety and efficacy.